<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682407</url>
  </required_header>
  <id_info>
    <org_study_id>OMS721-GNP-001</org_study_id>
    <nct_id>NCT02682407</nct_id>
  </id_info>
  <brief_title>Safety Study of IgAN, LN, MN, &amp; C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeros Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of OMS721 (narsoplimab)
      in subjects with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), Membranous
      Nephropathy (MN), and Complement Component 3 (C3) Glomerulopathy including Dense Deposit
      Disease. The study will also evaluate Pharmacokinetics (PK), Pharmacodynamics (PD), anti-drug
      antibody response (ADA), and neutralizing antibodies (NAb) of OMS721 when administered
      intravenously and when administered both intravenously and subcutaneously in subjects of
      Asian descent with IgA Nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cohort 2 and 3 subjects are randomized in a 1:1 fashion during the first 12 weeks of treatment. Cohort 1 and 4 are non-randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy subjects with treatment related adverse events (AE).</measure>
    <time_frame>up to 104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 4: Proportion of IgAN patients of Asian descent with treatment related AEs.</measure>
    <time_frame>38 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 4: Change from baseline in serum and urine complement component levels.</measure>
    <time_frame>38 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1-3: Change from baseline in serum narsoplimab concentrations.</measure>
    <time_frame>up to 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 4: Change from baseline in serum narsoplimab concentrations.</measure>
    <time_frame>38 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort1-3: Change from baseline in proteinuria.</measure>
    <time_frame>up to 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort1-3: Change from baseline in urine albumin/creatinine ratio.</measure>
    <time_frame>up to 104 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>IgAN</condition>
  <condition>Lupus Nephritis</condition>
  <condition>MN</condition>
  <condition>C3 Glomerulopathy</condition>
  <arm_group>
    <arm_group_label>OMS721 (narsoplimab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of OMS721 (narsoplimab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OMS721 (narsoplimab)</intervention_name>
    <description>Biological: OMS721 (narsoplimab)</description>
    <arm_group_label>OMS721 (narsoplimab)</arm_group_label>
    <other_name>narsoplimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age at screening and competent to provide informed consent; For
             Cohort 4 only, participants are of Asian descent

          -  Have a diagnosis of one of the following:

               1. IgAN on kidney biopsy

               2. LN, MN and C3 Glomerulopathy including Dense Deposit Disease on kidney biopsy and
                  24-hour Urine Protein Excretion (UPE) &gt; 1000 mg/24 hours (for Cohort 1 only)

               3. IgAN diagnosis is confirmed by biopsy within 8 years of screening for Asian
                  descent (for Cohort 4 only)

          -  For Cohort 4 only: subjects with IgAN of Asian descent, documented history of 24-hour
             UPE &gt; 1 g within 6 months prior to Screening or Urine Protein-Creatinine Ratio (uPCR)
             &gt; 0.75 by spot urine at screening

          -  Screening Estimated Glomerular Filtration Rate (eGFR) &gt;= 30 mL/min/1.73 m^2

          -  Are on physician-directed, stable, optimized treatment with angiotensin converting
             enzyme inhibitors (ACEI) and/or angiotensin receptor blockers (ARB) and have a
             systolic blood pressure of &lt; 150 mmHg and a diastolic blood pressure of &lt; 90 mmHg at
             rest

        Exclusion Criteria:

          -  Have a hemoglobin less than 9.0 g/dL

          -  Have a platelet count =less than 100,000/mm^3

          -  Have an absolute neutrophil count &lt;500 cells/mm^3

          -  Have an Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) greater
             than 5.0 x the upper limit of normal (ULN)

          -  Have systemic manifestations of Henoch-Schonlein purpura within 2 years prior to
             Screening

          -  Have used: belimumab, eculizumab, or rituximab within 6 months prior to Screening

          -  Have a history of renal transplant

          -  History of human immunodeficiency virus (HIV), evidence of immune suppression, active
             hepatitis C virus (HCV) infection (subjects with positive anti-HCV antibody

          -  Have a malignancy except for adequately treated and cured basal or squamous cell skin
             cancer, curatively treated in situ disease, or other cancer from which the patient has
             been disease-free for 5 years or more
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Omeros Clinical Trial Information</last_name>
    <phone>206-676-5000</phone>
    <email>ctinfo@omeros.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgAN</keyword>
  <keyword>Lupus Nephritis</keyword>
  <keyword>MN</keyword>
  <keyword>C3 Glomerulopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

